Legend Biotech (LEGN)
(Real Time Quote from BATS)
$48.62 USD
-2.21 (-4.35%)
Updated Sep 20, 2024 03:44 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LEGN 48.62 -2.21(-4.35%)
Will LEGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LEGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LEGN
Mortgage Rates Fall to a 12-Month Low
Pre-Markets in Red to Close an Eventful Week, Earnings Mixed
LEGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
Other News for LEGN
Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares
RA Capital Management L.P. Increases Stake in Janux Therapeutics Inc
Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum?London" to Discuss the Future Together
GenScript Appoints New Board Members to Drive Global Growth